Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer
Current preclinical models to investigate human HR + breast cancer progression and response to immunotherapy in vivo are limited. Here, the authors demonstrate that mammary tumours driven by a synthetic progestin combined with an oral carcinogen recapitulate several immunobiological features of huma...
Guardado en:
Autores principales: | Aitziber Buqué, Norma Bloy, Maria Perez-Lanzón, Kristina Iribarren, Juliette Humeau, Jonathan G. Pol, Sarah Levesque, Laura Mondragon, Takahiro Yamazaki, Ai Sato, Fernando Aranda, Sylvère Durand, Alexandre Boissonnas, Jitka Fucikova, Laura Senovilla, David Enot, Michal Hensler, Margerie Kremer, Gautier Stoll, Yang Hu, Chiara Massa, Silvia C. Formenti, Barbara Seliger, Olivier Elemento, Radek Spisek, Fabrice André, Laurence Zitvogel, Suzette Delaloge, Guido Kroemer, Lorenzo Galluzzi |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/a7e37a6ac2cb4091b97dc956fd1c341a |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Publisher Correction: Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer
por: Aitziber Buqué, et al.
Publicado: (2020) -
Immunological configuration of ovarian carcinoma: features and impact on disease outcome
por: Lorenzo Galluzzi, et al.
Publicado: (2021) -
Trial watch: intratumoral immunotherapy
por: Juliette Humeau, et al.
Publicado: (2021) -
Crizotinib and ceritinib trigger immunogenic cell death via on-target effects
por: Adriana Petrazzuolo, et al.
Publicado: (2021) -
Who guards the guardians?
por: Duncan Bloy
Publicado: (2012)